HCC

Laura Goff, MD, discussed the combination of atezolizumab plus bevacizumab in relation to its effect on the treatment paradigm of hepatocellular carcinoma during a presentation at the 17th Annual Meeting of the International Society of Gastrointestinal Oncology.

Although the use of α-fetoprotein has long been established in hepatocellular carcinoma as a biomarker for screening and diagnosis, its role in treatment selection and prognosis following systemic therapy is a moving target.

Ghassan K. Abou-Alfa, MD, discusses the evolution of the treatment landscape in hepatocellular carcinoma.

During a Targeted Oncology Case Based Peer Perspectives event, Ghasson K. Abou-Alfa, MD, reviewed the case of a 77-year old woman with hepatocellular carcinoma.

In an interview with Targeted Oncology, Ghassan K. Abou-Alfa, MD, discussed the evolution of the liver cancer treatment landscape and recognizes some of most important advances in the field during Liver Cancer Awareness Month.

Better response in survival were observed in patients with Child-Pugh B cirrhosis, a patient population that has limited treatment options, when given cabozantinib in the phase 3 CELESTIAL study.

Camrelizumab plus apatinib demonstrated a high objective response rate and disease-control rate, as well as durable responses and long survival as treatment of patients with advanced hepatocellular carcinoma, according to the results from the phase 2 RESCUE clinical trial.

The sintilimab injection in combination with IBI305, a biosimilar to bevacizumab, improved overall survival as well as progression-free survival compared with sorafenib as front-line treatment of patients with advanced hepatocellular carcinoma, meeting the predefined primary end point of the phase 3 ORIENT-32 clinical trial.

A significant improvement in overall survival was observed with the addition of hepatic arterial infusion chemotherapy to oxaliplatin, fluorouracil, and leucovorin compared with transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.

“In sum, these data show that T300+D regimen provides the best benefit-to-risk profile across arms,” Robin Kate Kelley, MD, said of Study 22 in hepatocellular carcinoma.

Bruno Sangro, MD, PhD, discusses the key takeaways from recent data in the treatment landscape of patients with hepatocellular carcinoma.

Regorafenib demonstrated a tolerable safety profile as treatment of patients with unresectable hepatocellular carcinoma in the real world, according to results from the ongoing prospective observational REFINE study.

In an interview with Targeted Oncology, Mehmet Akce, MD, discussed the treatment options available for patients with advanced hepatocellular carcinoma and how he would go about sequencing these treatments in his practice.

Mehmet Akce, MD, discusses how he treats patients with advanced hepatocellular carcinoma in the first-line setting.

Patients with hepatocellular carcinoma, or primary liver cancer, treated with ThermoDox plus radiofrequency ablation in the phase 3 OPTIMA clinical trial will continue to be followed for overall survival.

Lenvatinib may benefit patients with advanced hepatocellular carcinoma with second- or later-line therapies and a high burden of intrahepatic lesions.

The independent Data Monitoring Committee recommended stopping the global phase 3 OPTIMA clinical trial evaluating the combination of ThermoDox with radiofrequency ablation in hepatocellular carcinoma or primary liver cancer.

The last patient with advanced hepatocellular carcinoma was enrolled on the phase 2 HEPANOVA trial, which is investigating the combination of Tumor Treating Fields and sorafenib. The combination showed safety and tolerability for patients in an interim analysis.

Lipika Goyal, MD, discusses first-line options for patients with patients with hepatocellular carcinoma.

The FDA has issued a complete response letter in regard to the applications for potential accelerated approval of pembrolizumab in combination with lenvatinib as treatment of patients with previously untreated, unresectable hepatocellular carcinoma.

TXR-311 has demonstrated activity in validation studies and has selectivity for killing hepatocellular carcinoma tumor cells.

Richard S. Finn, MD, discusses how he sees the field of hepatocellular carcinoma evolving in the future.

In a Targeted Oncology case-based peer perspectives live discussion, David H. Ilson, MD, PhD, discusses the treatment options for patients with hepatocellular carcinoma

“For the first-time we have a regimen that markedly improves survival over sorafenib, the standard of care for first-line hepatocellular carcinoma since 2007, and offers patients the opportunity for improved disease control with a favorable tolerability profile.”

David J. Pinato, MD, PhD, discusses past and current trials that are significant for the hepatocellular carcinoma patient population.

Based on data from a matching-adjusted indirect comparison study, cabozantinib the safety and efficacy of cabozantinib may be comparative to regorafenib in advanced hepatocellular carcinoma.

In an interview with Targeted Oncology, Yujin Hoshida, MD, PhD, discussed the next steps for improving upon the current understanding of hepatocellular carcinoma subtypes to improve responses and outcomes in patients.

Anjana Pillai, MD, discusses challenges for treating patients with hepatocellular carcinoma.

"Having obtained an encouraging proof-of-concept for the liver-cancer directed effect of MIV-818 in phase Ia, we hope to get additional supportive data from the phase Ib study. We believe that MIV-818 has the potential to provide liver cancer patients with major therapeutic benefits."

“If we’re going to get patients to second-line treatment, we have to get them to front line. That has to do with transitioning patients from locoregional therapy appropriately."